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Donor specific transfusions or cyclosporine for related-donor kidney
transplantation? DST and cyclosporine are two immunosuppressive
strategies to improve first year graft survival in high MLC, one-
haplotype matched, living-related donor kidney transplantation. How-
ever, each has disadvantages: The conventional strategy of DST may
sensitize the recipient to donor antigens, precluding transplantation
from that donor, and cyclosporine may increase graft failure due to
nephrotoxicity. We used decision analysis to compare these two
strategies. We assumed that the risk of sensitization by DST is 12%,
that graft failure in the first year is equal in both strategies, but that the
annual probability of graft failure in later years is 2.6% with DST and
from 2.7% to 3.6% with cyclosporine. Patients sensitized by DST and
patients with graft failure undergo dialysis while awaiting cadaveric
donor transplantation using cyclosporine. Outcomes were assessed as
quality-adjusted years of survival. The analysis was deliberately biased
to favor DST, the conventional strategy. Quality-adjusted life expect-
ancy for a 40-year-old patient in both strategies is from 17.7 to 19.1
years. The difference between the DST and cyclosporine strategies
ranges from —0.7 to +0.6 years. Given current data on sensitization by
DST, long-term cyclosporine nephrotoxicity, and deliberate biases
favoring the DST strategy, we conclude that there is no substantive
advantage of the DST strategy. Cyclosporine is equally efficacious for
recipients of high MLC, one-haplotype matched kidney transplants,
and may be preferred for transplants from more distant relatives and
unrelated living donors.
Tissue matching strongly influences the results of kidney
transplantation from related donors. It is well known that graft
survival in recipients of two-haplotype matched transplants
exceeds that in less well matched donor-recipient pairs. Among
one-haplotype matched relatives, reactivity of the mixed lym-
phocyte culture (MLC) predicts graft survival. Using azathio-
prine and prednisone as maintenance immunosuppression, re-
cipients with a low (weakly reactive) MLC with their donor
have results similar to two-haplotype matched relatives,
whereas recipients with a high (strongly reactive) MLC expe-
rience lower graft survival [I]. Unfortunately, the vast majority
of one-haplotype matched pairs have a high MLC.
Two innovative approaches attempt to minimize graft rejec-
tion for this group of patients. The conventional strategy uses
blood transfusions from the kidney donor before transplanta-
tion, donor-specific transfusions (DST), followed by mainte-
nance immunosuppression with azathioprine and prednisone
[2—4]. Recently, another strategy has been proposed in which
DST is not employed prior to transplantation, but maintenance
immunosuppression is with cyclosporine and prednisone [5].
Both approaches improve first year patient and graft survival,
but each strategy presents a unique trade-off.
DST sensitizes some potential recipients to donor blood
antigens, thereby precluding transplantation from that donor.
Furthermore, sensitization may also preclude transplantation
from other related donors. Sensitized patients undergo dialysis
and may obtain a cadaver kidney; however, the long-term
results of both dialysis and cadaver transplantation are inferior
to the results of living related transplantation.
Cyclosporine immunosuppression, in contrast, does not sen-
sitize potential donors and provides all recipients with the
benefits of a living related transplant. However, there is a
possibility of graft loss due to long-term nephrotoxicity. The
nephrotoxicity of cyclosporine has been well documented in
recipients of heart, liver, and bone marrow transplants, and in
patients treated for autoimmune diseases, but the long-term
effect on kidney graft survival is not known.
Recently, several investigators have reported that there are
no significant differences in the outcomes of patients treated
with these two strategies [6—8]. However, the number of
patients reported in these studies is too small and the follow-up
is too short to detect a possible long-term advantage of DST.
Moreover, the studies did not consider differences in quality of
life of patients maintained on dialysis compared to patients with
successful kidney transplants.
We used decision analysis to compare these two strategies.
The results of our decision analysis demonstrate that DST is not
the preferred strategy; cyclosporine appears equally effica-
cious.
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Structure of the analysis
Decision analysis is a technique for choosing between alter-
native strategies [9]. To analyze a decision, the strategies are
defined, the subsequent clinical events for each strategy are
described, the probability of each event is specified, a value
(utility) for each final event is assigned, and the expected utility
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for each strategy is calculated. The strategy with the greatest
expected utility is the preferred choice. The structure of the
analysis is described briefly below. Detailed explanations of the
assumptions, Markov models, probabilities and calculations
that we employed in the analysis are given in the Appendix.
Decision tree
In Figure 1 the two strategies, DST and cyclosporine, are
represented by the two branches emanating to the right from the
square node. Initially all patients are unsensitized. The round
node on the DST branch (top branch) indicates that patients in
this strategy may or may not become sensitized to their donor
following transfusion. Sensitized patients (top branch) cannot
undergo transplantation from that donor and remain on dialysis
while awaiting a cadaver kidney. Patients not sensitized
(bottom branch) receive a living related graft and are immuno-
suppressed with azathioprine and prednisone. Patients in the
cyclosporine strategy (bottom branch) are not at risk of sensi-
tization, receive a living related graft and are immunosup-
pressed with cyclosporine. The three outcomes of this decision
tree are 1) patients on dialysis awaiting cadaver kidney transplan-
tation, 2) patients undergoing living related kidney transplantation
without delay and immunosuppressed with azathioprine, and 3)
patients undergoing living-related kidney transplantation with-
out delay and immunosuppressed with cyclosporine. These
three outcomes are represented by the rectangles and described
in the Markov models of prognosis.
Markov models of prognosis
The subsequent clinical course after dialysis and transplan-
tation is a complicated sequence of events. The Markov model
represents these events first by dividing the future into a
number of equal time intervals, and second by defining a series
of health states and the possible transitions that may occur
among them in each interval. Life expectancy is calculated from
the length of the intervals and the transition probabilities [10].
For our analysis, we defined three health states: 1) WELL
WITH GRAFT, 2) DIALYSIS, and 3) DEAD. Several modifi-
cations of these states are included in the complete model as
explained in the Appendix. The probabilities of transition
among these states are discussed below and described in detail
in the Appendix. Values (utilities) for each health state are given
below.
Summary of the data used
Probabilities. We calculated values for probabilities from
data in the medical literature and when data were not available,
from our own estimates [11—41] (Table 1). The justifications for
these values are explained in the Appendix. Except for sensiti-
zation by DST, the likelihoods of subsequent clinical outcomes
are expressed as probabilities per year of follow-up, because
this is the conventional method of reporting results of clinical
trials. The method used to convert these annual probabilities to
the transition probabilities for calculations in the Markov model
is described in the Appendix.
Because there are insufficient data in the literature on the
long-term effect of cyclosporine nephrotoxicity on graft sur-
vival, it was necessary to make several assumptions in assign-
ing the probability of graft loss in patients treated with cyclo-
sporine. As discussed later, these assumptions bias the analysis
in favor of the DST strategy. First, we assumed that the graft
loss in patients treated with azathioprine is from rejection due
to differences in tissue matching, with a lower annual probabil-
ity of graft loss in recipients of transplants from living-related
donors. We assumed that graft loss in patients treated with
cyclosporine, however, is the combined effect of rejection and
nephrotoxicity due to cyclosporine. Thus, the annual probabil-
ity of graft loss in recipients of transplants from living-related
and cadaver donors treated with cyclosporine is the sum of the
annual probability of graft loss due to rejection and the annual
probability of graft failure due to nephrotoxicity. Second, we
assumed that the annual probability of graft failure due to
rejection is the same in both strategies. Thus, the annual
probability of graft loss in patients treated with cyclosporine is
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Fig. 1. The decision tree.
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Table 1. Probabilities and utilities used in baseline and sensitivity
analyses
Range
tested in
sensitivity
Probabilities Baseline value
0.12
analyses
0.0 to 0.5
Table 2. Sources of bias
0.5
0.1
0.1
Strategy
Bias favored
I. Low value for probability of sensitization with DST. DST
2. High value for probability of graft loss due to DST
rejection in subsequent years in patients treated with
cyclosporine.
3. High value for probability of graft loss due to DST
nephrotoxicity in subsequent years in patients treated
with cyclosporine.
0.0 to 0.2
0.0 to 0.2
0.0 to 0.2
0.0 to 0.2
0.0 to 0.3
0.0 to 0.3
0.0 to 0.3
0.0 to 0.5
Sensitization by DST
Annual probability of cadaver
kidney transplantation:
following sensitization with DST
following failed graft
Annual probability of death
for patients on dialysis
First year mortality after
transplantation
first transplant:
living related (DST strategy)
living related (cyclosporine
strategy)
cadaver
2nd or 3rd transplant: cadaver
First year graft failure:
first transplant:
living related (DST strategy)
living related (cyclosporine
strategy)
cadaver
2nd or 3rd transplant: cadaver
Annual probability of death after
the first year:
living related (DST strategy)
living related (cyclosporine
strategy)
cadaver
Annual probability of graft loss
after the first year
Due to rejection:
living related (DST strategy)
living related (cyclosporine
strategy)
cadaver
Due to cyclosporine nephrotoxicity:
living related (DST strategy)
living related (cyclosporine
strategy)
cadaver
Due to rejection and
nephrotoxicity combined:
living related (DST strategy)
living related (cyclosporine
strategy)
cadaver
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Quality of life adjustment factors:
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the probability of graft loss in one-haplotype matched, living-
related recipients and in cadaver transplant recipients. These
0.0 two estimates are the clinically relevant upper and lower
0.0 to o.os bounds for graft loss due to the nephrotoxicity of cyclosporine.
Details regarding calculation of the annual probability of graft
0.0 to 0.05 loss are provided in the Appendix.
The probabilities for the baseline and sensitivity analyses are
0.0 to 0.06 given in Table 1, including the minimal and maximal estimates
0.0 to 0.06 for graft loss due to cyclosporine nephrotoxicity. For the
sensitivity analyses, we varied these baseline values throughout
0.0 to 0.07 the range indicated to test the effect on the results.
Utilities. The outcomes are expressed in quality adjusted
— years of survival. Forty years is the approximate average age of
0.0 to 1.0 patients in reports on long-term recipient and graft survival
— after transplantation. Therefore we calculated survival for
patients aged 40 years at the time of the initial decision. We
assumed patients may receive a graft through the age of 65
years. We assigned a value for the quality of life of each of the
possible health states (Table 1). WELL WITH GRAFT is
assigned a value of 1.0. Patients on chronic dialysis have a
0.0
0.001 or 0.010
0.001 or 0.010
0.026
0.027 or 0.036
0.035 or 0.044
1.0
0.7
0.0
higher than in patients treated with azathioprine. Third, we
assumed that the probability of graft loss due to the nephrotox-
icity of cyclosporine is similar in magnitude to the probability of
graft loss due to rejection caused by differences in tissue
matching between donor and recipient pairs. We assigned
minimal and maximal estimates for the annual probability of
graft loss attributable to cyclosporine nephrotoxicity as follows:
the minimal estimate is similar to the probability of graft loss in
HLA-identical (two-haplotype matched) living-related recipi-
ents; the maximal estimate is similar to the difference between
poorer objective and subjective quality of life compared to
patients with functioning grafts [42—44]. DIALYSIS is assigned
a value of 0.7. This value was varied in sensitivity analysis.
DEAD is assigned a value of 0. The quality adjusted survival of
a patient in each strategy is the sum of the number of years in
each state multiplied by the value for the quality of life for that
state.
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Sensitivity analysis
We tested the effect of different assumptions by substituting
a wide range of values for baseline probabilities and utilities
(Table 1). The results show that the difference in expected
utility between the DST and cyclosporine strategies is influ-
enced most by the probabilities for cyclosporine nephrotoxicity
and sensitization by DST. For differences in each of the other
probabilities and utilities, the absolute difference between ex-
pected utilities of the DST and cyclosporine strategies remain
below one quality-adjusted year of life expectancy throughout
the range of values indicated.
Probability of cyclosporine nephrotoxicity. Figure 3 shows
the expected utility for each strategy over a wide range of
annual probabilities of graft loss attributable to cyclosporine
nephrotoxicity. The baseline values (0.001 and 0.01) are shown
as solid vertical lines. The threshold value of 0.006 (one graft
loss per 167 patients per year) is shown as the left dashed
vertical line. Above this threshold probability DST is preferred,
however, DST is preferred by less than one year unless the
probability of graft loss attributable to cyclosporine toxicity is
greater than 0.015 (one graft loss per 70 patients per year) as
shown by the right dashed vertical line. This value is far higher
than values reported in the literature for kidney transplant
recipients treated with cyclosporine. Throughout the range of
values that are reasonable, DST is not strongly preferred.
Probability of sensitization by DST. Figure 4A and 4B show
the effect of a range of probabilities for sensitization by DST for
each of the two baseline annual probabilities of graft loss
attributable to cyclosporine toxicity. Each figure indicates the
baseline probability for sensitization with DST, 0.12 (solid
vertical line). If the risk of cyclosporine toxicity is low (Fig.
4A), the threshold value below which the DST strategy is
preferred over the cyclosporine strategy (left dashed vertical
0.001 0.006 0.01 0.015
Base- Thres- Base- 1 Year
line hold line difference
0.05
Fig. 3. One-way sensitivity analysis: The
annual probability of graft loss attributable to
cyclosporine nephrotoxicity.
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Sources of bias. As described earlier, we made several
assumptions that deliberately bias the analysis in favor of the
DST strategy in order to avoid overlooking an advantage of the
conventional strategy. The sources of bias are listed in Table 2.
Calculations. Calculations of expected utility were per-
formed using Decision Maker 6.0, a computer program de-
signed for decision analysis [45].
Results
Baseline analysis
Results of the baseline analysis are given in Figure 2. We
calculated expected utilities for each strategy using two as-
sumptions for the annual probability of graft failure from
cyclosporine nephrotoxicity. If the probability is as high as
0.0 10, the expected utility of the DST strategy exceeds that of
the cyclosporine strategy by 0.6 quality-adjusted years (7.2
quality-adjusted months). We interpret this difference as the
maximal advantage of the DST strategy over the cyclosporine
strategy. Considering the overall survival of approximately 18
quality-adjusted years and the deliberate biases favoring the
DST strategy, we consider a maximal advantage of DST of only
7.2 quality-adjusted months to be of uncertain clinical signifi-
cance. On the other hand, if the probability of cyclosporine
toxicity is 0.001, the expected utilities of both strategies rise and
the expected utility of the cyclosporine strategy exceeds that of
the DST strategy by 0.7 quality-adjusted years (8.4 quality-
adjusted months). Therefore, using baseline values for proba-
bilities and utilities, we conclude that the conventional strategy,
DST and azathioprine, does not appear to provide a substantial
benefit over cyclosporine; cyclosporine is as efficacious. In
order to determine if our assumptions influenced our conclu-
sions, we performed an extensive sensitivity analysis.
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Fig. 4. One-way sensitivity analysis: The risk
of sensitization by DST. Annual probability of
graft loss attributable to cyclosporine
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line) is 0.02, a value that is well below the risk of sensitization
reported in the literature. The expected utility of the DST
strategy does not exceed that for cyclosporine by more than one
year even if the risk of sensitization by DST is zero. However,
if the risk of cyclosporine toxicity is high (Fig. 4B), the
threshold value of 0.19 (right dashed vertical line) is just above
the baseline probability and is well within the range of values
reported for patients at high risk of sensitization, such as
multiparous women and patients with antibodies to HLA [46,
47]. A one year advantage of DST occurs only if the probability
of sensitization is extremely low, less than 0.045. Given the
many sources of bias in favor of the DST strategy, these
analyses confirm that the DST strategy is not strongly pre-
ferred.
We also tested the effect of simultaneous differences in the
probabilities of sensitization by DST and graft loss due to
cyclosporine nephrotoxicity (Fig. 5). For combinations of prob-
abilities which lie below the bold line labelled NO DIFFER.
ENCE (the threshold line), the DST strategy is preferred over
the cyclosporine strategy. The shaded region indicates proba-
bilities for which the expected utility of the DST strategy
exceeds that of the cyclosporine strategy by less than one year.
C0
N
0C,-.DU)
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.000
As discussed earlier, we consider an advantage of DST of this
magnitude to be of uncertain clinical significance. For combi-
nations of probabilities which lie within this range, we consider
the decision to be a toss-up [48, 49]. Below the shaded region,
the expected utility of the DST strategy exceeds that of the
cyclosporine strategy by more than one year and is strongly
preferred. For combinations of probabilities which lie above the
threshold line, cyclosporine is the preferred strategy. Above the
dashed line, the cyclosporine strategy is preferred by more than
one year. For all reasonable combinations of probabilities, DST
is not strongly preferred.
Annual probabilities of death and graft failure. The transition
probabilities for the Markov model are based on a follow-up
period of approximately 10 years. As discussed earlier, life
expectancy for a 40-year-old patient is approximately 18 qual-
ity-adjusted years. During this interval, the annual probabilities
of death and graft failure may increase rather than remain
constant. Therefore, we performed another sensitivity analysis
to examine the effect of gradually increasing annual probabili-
ties of death and graft failure from the baseline values to two
times these values as the patient ages from 40 to 80 years. Given
these new assumptions, quality-adjusted life expectancy de-
creases to approximately 12 years for both strategies, but the
difference between DST and cyclosporine strategies declines to
less than two months. Therefore, cyclosporine remains an
equally efficacious strategy, even if the annual probabilities of
death and graft failure increase rather than remain constant,
Conclusions
Our results indicate that the conventional strategy of DST
with azathioprine is not clearly preferred over the strategy using
cyclosporine without DST. Both strategies provide approxi-
mately 18 quality-adjusted years of survival, but the absolute
difference in expected utilities between the DST and cyclospo-
rifle strategies is only 0.6 to 0.7 quality-adjusted years (7.2 to 8.4
quality-adjusted months) of survival (Fig. 2). Extensive sensi-
tivity analysis reveals that the difference in expected utilities
between the two strategies is influenced most strongly by the
probabilities of graft failure attributable to cyclosporine neph-
rotoxicity and of sensitization by DST. Within the range of
values that have been reported in the literature (Table 1), the
difference in expected utility remains less than one quality-
adjusted year of survival (Figs. 3 to 5). Given the current data
on sensitization by DST and graft loss due to cyclosporine
nephrotoxicity, and considering the deliberate biases favoring
DST, we conclude there is no substantive advantage of the DST
strategy. Thus, we conclude that the strategy of cyclosporine
immunosuppression without DST for one-haplotype matched,
high MLC, living-related donor transplantation is as efficacious
as the conventional strategy of DST with azathioprine immu-
nosuppression. In view of the extensive sensitivity analyses
that do not change the results, this conclusion is robust.
Our review of the literature indicates that the long-term
nephrotoxicity of cyclosporine is not yet known with certainty.
Although structural, functional, and clinical renal abnormalities
due to cyclosporine are well documented, progressive damage
leading to renal failure attributable to cyclosporine has not been
observed in patients receiving cyclosporine in the doses cur-
rently used in renal transplantation. Indeed, the few studies that
report more than a three to four year follow-up do not show an
increase in the probability of graft failure in renal transplant
recipients treated with cyclosporine compared to patients
treated with azathioprine [40, 41]. Additional studies with
longer follow-up are necessary to determine the probability of
graft failure due to cyclosporine nephrotoxicity, and to deter-
mine whether the probability of graft failure due to nephrotox-
icity exceeds the increased probability of graft survival due to
the superior immunosuppressive properties of cyclosporine. At
the present time, the best evidence indicates that the risk of
graft failure due to cyclosporine toxicity is less than 1% per
year, the maximal estimate for the probability in the baseline
analysis. Thus, given the current information on long-term
cyclosporine nephrotoxicity, cyclosporine immunosuppression
appears as efficacious as DST with azathioprine immunosup-
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pression for one-haplotype matched, high MLC, living-related suppression either with DST and azathioprine or with cyclo-
donor renal transplantation.
This analysis shows that the DST with azathioprine and
cyclosporine strategies are equally efficacious with regard to life
expectancy and the quality of life on dialysis and after trans-
plantation. Therefore both strategies are equally justifiable; the
decision between the two strategies is a "toss-up". Toss-ups
recently have been identified in many clinical investigations of
diagnostic and therapeutic decision making [48, 49]. In this
analysis, it is important to note that we have not considered all
factors that may be relevant to clinical decision making in
individual patients. For example, we have not considered the
potential impact on the related donor of sensitization of the
recipient by DST. Of course, potential donors who are excluded
from donating are not exposed to the risks of donor nephrec-
tomy; however, neither do they derive the benefit of kidney
donation [50—53]. We have also not considered monetary costs
of transfusions, azathioprine, cyclosporine and the procedures
for monitoring the results of both immunosuppressive strate-
gies. Both strategies are very expensive, and if there is a
significant difference in cost, it might have an important bearing
on decision making for individual patients and for health care
policy. Finally, we did not consider the supply and demand for
kidneys from living-related and cadaver donors. Using cadaver
kidneys for patients sensitized by DST to their potential living-
related donor reduces the number of cadaver kidneys available
for patients without a suitable related living donor. Given the
large number of patients already waiting for cadaver kidneys, a
strategy which wastes living-related donor kidneys is undesir-
able. The model and the data that we present here could be used
to address these additional questions.
How is our conclusion different from the results of recent
clinical studies that show no difference in outcomes of patients
treated by each strategy [6—8]? These studies have a number of
serious short comings: First, not all studies reported the out-
come of recipients who were sensitized by DST and who
therefore did not receive a living-related transplant. Second, the
difference in quality of life between patients on dialysis and
those with successful transplants was not considered. Third,
the follow-up was too short to detect possible long-term adverse
consequences of cyclosporine nephrotoxicity. Finally, the num-
ber of patients studied was too small to detect a possible
long-term advantage of DST, if it exists.
This final criticism is especially important. Because long-term
graft survival following transplantation in the DST strategy is
high, in order to detect a statistically significant difference in
long-term results between DST and cyclosporine strategies, it
would be necessary either for the difference in the proportion of
failed grafts to be relatively high, or for the number of patients
who are studied to be extremely large. For example, to detect a
difference in graft survival between these two strategies of only
7.5% at 5 years (70% vs. 77.5% survival), approximately 1200
patients would be required in a clinical trial [54]. The recently
reported studies have included less than 120 patients. There-
fore, they do not have sufficient statistical power to detect a
difference between these two strategies, if such a difference
exists. In order to answer this question, a large multi-institu-
tional trial would be required. Our analysis does not substitute
for a clinical trial. However, until an adequate clinical trial of
these two strategies is completed, we conclude that immuno-
sporine is justifiable for patients with a one-haplotype matched,
high MLC, living related donor.
Our results also may be applicable to transplants from more
distant relatives from unrelated living donors. Although there is
virtually no long-term data regarding the results of these trans-
plantations, there is considerable interest in using these donors
[55]. The risk of sensitization by DST for zero-haplotype
matched related or unrelated recipients is higher than for
one-haplotype matched recipients [46, 47, 56, 57]. However,
there is no reason to expect that cyclosporine toxicity is greater
in these recipients. As shown in Figures 4A and 4B, given a
higher risk of sensitization, but the same risk of cyclosporine
nephrotoxicity, cyclosporine immunosuppression would be
preferred for transplants from more distant relatives or from
unrelated living donors.
Acknowledgments
This work was supported in part by training grant LM7044 and
research grant LM4493 from the Medical Information Program, Na-
tional Library of Medicine, Bethesda, Maryland, USA. Technical
assistance on portions of this project was kindly provided by Stephen
G. Pauker, M.D., John B. Wong, M.D., Craig Fleming, M.D., and
other members of the Division of Clinical Decision Making, New
England Medical Center Hospital.
Reprint requests to Andrew Levey, M.D., Box 784, New England
Medical Center, 750 Washington Street, Boston, Massachusetts 02111,
USA.
References
I. TIwARI JL, SASAKI N: Mixed lymphocyte culture response and
graft survival in living-related kidney transplants, in Clinical Kid-
ney Transplants: 1985, edited by TERASAIU Pt, Los Angeles,
UCLA Tissue Typing Lab, 1985, p. 227
2. GLAsS NR, MIILER DT, SOLLINGER HW, BELZER FO: Compara-
tive analysis of the DST and Lmuran-plus-DST protocols for live
donor renal transplantation. Transplantation 36:636—641, 1983
3. SALVATIERRA 0, VINCENTI F, AMEND W, POTTER D, IwAKI Y,
OPELZ G, TERASAKI P. DUCA R, COCHRAN K, HANES D, STONEY
RJ, FEDUSKA NJ: Deliberate donor-specific blood transfusions
prior to living-related renal transplantation: A new approach. Ann
Surg 192:543—552, 1980
4. ANDERSON CB, SICARD GA, RODEY GE, ANDERMAN CK, ETHER-
EDGE EE: Renal allograft recipient pre-treatment with donor-
specific blood and concomitant immunosuppression. Transplant
Proc l5:939—942,1983
5. FLECHNER SM, KERMAN RH, VAN BUREN C, KAHAN BD: Suc-
cessful transplantation of cyclosporine treated haploidentical liv-
ing-related renal recipients without blood transfusions. Transplan-
tation 37:73—76, 1984
6. VERGNE-MARLNI PJ, LANGLEY JW, PARKER TF, DICKERMAN R,
LAND GA, MA! M: Influence of donor specific transfusion and
cyclosporine in related recipients of one-HLA haplotype mis-
matched kidneys. (abstract) Abstracts of the American Society of
Transplant Physicians 6th Annual Meeting, 1987, p. 32
7. SOMMER BG, HENRY ML, BOWERS VD, FERGUSON RM: Mis-
matched living related donor transplants: donor specific transfu-
sions vs. cyclosporine. (abstract) Abstracts of the American Soci-
ety of Transplant Surgeons 13th Annual Meeting, 1987, p. 63
8. LEIVSTAD T, ALBRECHSTEN D, FLATMARK A, THORSBY E: Renal
transplants from HLA-haploidentical living-related donors: The
influence of donor-specific transfusions and different immunosup-
pressive regimens. Transplantation 42:35—38, 1986
9. PAUKER SG, KASSIRER JP: Decision analysis. N EngI J Med
316:250—258, 1987
492 Jayes and Levey: Related donor transplantation
10. BECK JR, PAUKER SG: The Markov process in medical prognosis.
Med Decis Making 3:419—458, 1983
11. SALVATIERRAO, MELZERJ, POTTERD, GARAVOY M, VINcENTI F,
AMEND WJC, HUSING R, HOPPER S, FEDUSKA NJ: A seven year
experience with donor-specific blood transfusions. Transplantation
40:654—659, 1985
12. GLASS NR, MILLER DT, SOLLINGER HW, BELZER OF: A four-year
experience with donor blood transfusion protocols for living-donor
renal transplantation. Transplantation 39:615—619, 1985
13. KRAMER P, BROYER M, BRUNNER FP, BRYNGER H, CHALLAH S,
OULES R, RIZzONI 0, SELWOOD NH, WING AJ, BALAS EA:
Combined report on regular dialysis and transplantation in Europe
XVI, 1983. Proc Eur Dial Transplant Asso 21:5—68, 1984
14. SANFILIPPO F, VAUGHN WF, BOLLINGER RR, SPEES EK: Compar-
ative effects of pregnancy, transfusion, and prior graft rejection on
sensitization and renal transplant results. Transplantation 34:360—
366, 1982
15. SALVATIERRA 0, IWAKI Y, VINCENTI F, AMEND W, POTTER D,
OPELZ G, TERASAKI P, DUCA R, HOPPER S, FEDUSKA N: Inci-
dence, characteristics, and outcome of recipients sensitized after
donor-specific blood transfusion. Transplantation 32:528—531, 1981
16. End-Stage Renal Disease Network Coordinating Council: Program
Report 1984. Tampa Fla: National Forum of End-Stage Renal
Disease Networks, 1985
17. EGGERS PW, CONNERTON R, MCMULLAN M: The Medicare expe-
rience with end-stage renal disease: Trends in incidence, preva-
lence, and survival, Health Care Financing Review 5:69—79, 1984
18. ROSANSKY SJ, SuGIM0TO T: An analysis of the United States renal
transplant patient population and organ survival characteristics
1977 to 1980. Kidney mt 22:685—692, 1982
19. WELLER JM, PORT FK, SCHWARTZ RD, FERGUSON W, WILLIAMS
GW, JACOBS JF: Analysis of survival of end-stage renal disease
patients. Kidney mt 21:78—83, 1982
20. WING AJ, BRUNNER FP, BRYNGER H, et al: Combined report on
regular dialysis transplantation in Europe. \l1I, 1977. ProcEur
Dial Transplant Assoc 16:2—76, 1978
21. VOLLMER WM, WARL PW, BLAGG CR: Survival with dialysis and
transplantation in patient with end-stage renal disease. N Engl J
Med 308:1553—1558, 1983
22. KRAKAUER H, GRAUMAN JS, MCMULLAN MR, CREEDE CC: The
recent U.S. experience in the treatment of end-stage renal disease
by dialysis and transplantation. N EngI J Med 308:1558-1563, 1983
23. ROBERTS SD, MAXWELL DR, GROSS TL: Cost-effective care of
end-stage renal disease. A billion dollar question. Ann Intern Med
92:243—248, 1980
24. MATAS AJ, TELLIS VA, VEITH FJ, KUEMMEL P, MOLLENKOPF F,
KARWA 0, SOBERMAN RJ: The fate of the patient returned to
hemodialysis after losing a renal transplant. JAMA 250:1053—1056,
1983
25. TERASAKI P1, TOYOTONE A, MICKEY MR. CICCIARELLI J, IWAKI
Y, CECKA M, TIwARI J: Patient, graft, and functional survival
rates: An overview, in Clinical Kidney Transplants: 1985, edited by
TERASAKI P1, Los Angeles, UCLA Tissue Typing Lab. 1985, p. 20
26. OPELZ G, MICKEY MR, TERASAKI P1: Calculations on long-term
graft and patient survival in human kidney transplantation. Trans-
plant Proc 9:27—30, 1977
27. FERGUSON RM, RYNASIEWICZ JJ, SUTHERLAND DER, SIMMONS
RL, NAJARIAN JS: Cyclosporin A in renal transplantation: A
prospective randomized trial. Surgery 92:175—182, 1982
28. The Canadian Multicentre Transplant Study Group: A randomized
clinical trial of cyclosporine in cadaveric renal transplantation. N
EnglJMed3O9:809—815, 1983
29. The Canadian Multicentre Transplant Study Group: A randomized
clinical trial of cyclosporine in cadaveric renal transplantation.
Analysis at three years. N EngI J Med 314:1218-1225, 1986
30. European Multiceitre Trial: Cyclosporine in cadaver renal trans-
plantation: One-year follow-up. Lancet 2:986—989, 1982
31. PORTER GA, BENNE1-I- WM: Chronic cyclosporine-associated
nephrotoxicity. Transplant Proc l3(Suppl l):20.4—207, 1986
32. BENNETT WM, PULLIAM JP: Cyclosporine nephrotoxicity. Ann
Intern Med 99:851—854, 1983
33. MYERS BD: Cyclosporine nephrotoxicity. Kidney mt 30:964—974,
1986
34. MYERS BD, Ross J, NEWTON L, LUETSCHER J, PERLROTH M:
Cyclosporine-associated chronic nephropathy. N EngI J Med 311:
699—704, 1984
35. MORAN M, TOMLANOVICH S, MYERS BD: Cyclosporine-induced
chronic nephropathy in human recipients of cardiac allografts.
Transplant Proc 375:185—190, 1985
36. PALESTINE AG, AUSTIN HA, BALOW JE, ANTONOVYCH TT, SAB-
NIS SO, PREUSS HG, NUSSENBLATT RB: Renal histopathologic
alterations in patients treated with cyclosporine for uveitis. N EnglJMed 314:1293—1298, 1986
37. BERG JK, FORRE 0, BJERKHOEL F, AMUNDSEN E, DJOSELAND 0,
RUGSTAD HE, WESTRE B: Side effects of cyclosporin A treatment
in patients with rheumatoid arthritis. Kidney mt 29:1180—1187, 1985
38. VON GRAFFENRIED B, HARRISON WB: Renal function in patients
with autoimmune disease treated with cyclosporine. Transplant
Proc 37:215—231, 1985
39. FEUTREN G, ASSAN R, KARSENTY G, DURO5TU H, SIRMAI J,
PAPOZ L, VIALLETTES B, VEXIAU P, RODIER M, LALLEMAND A,
BACH JF: Cyclosporin increases the rate and length of remissions in
insulin-dependent diabetes of recent onset. Lancet 2:119—123, 1986
40. MERION RM, WHITE DiG, THIRU S. EVANS DB, CALNE RY:
Cyclosporine: Five years' experience in cadaveric renal transplan-
tation. N Engl J Med 310:148—154, 1984
41. KAHAN BD, LORBER MI, FLECHNER SM, GOLDEN D, CONLEY 5,
VAN BUREN CT: Complications of cyclosporine-prednisone immu-
nosuppression in 402 renal allograft recipients exclusively followed
at a single center for 1—5 years. Transplantation 43:197—204, 1987
42. CUCHURAL GJ, LEVEY AS, PAUKER SO: Kidney failure or cancer:
Should immunosuppression be continued in a transplant patient
with malignant melanoma? Med Decis Making 4:83—107, 1984
43. EVANS RW, MANNINEN DL, GARRISON LP, HART LG, BLAGG CR,
GUTMAN RA, HULL AR, LOWRIE EG: The quality of life of
patients with end-stage renal disease. N Engl J Med 312:553—558,
1985
44. JOHNSON JP, MCCAULEY CR, COPLEY JB: The quality of life of
hemodialysis and transplant patients. Kidney mt 22:286-291, 1982
45. SONNENBERG FS, PAUKER SG: Decision Maker: An advanced
personal computer tool for clinical decision analysis, in Demonstra-
tion Digest of the 11th Annual Symposium for Computer Applica-(ions in Medical Care, edited by STEAD W, Washington, D.C.,
Symposium for Computer Applications in Medical Care, 1986
46. BURLINGHAM Wi, STRATTA RJ, ARMBRUST MJ, SOLLINGER 11W,
KALAYONGLU M, BELZER FO: Muttivariate analysis of risk factors
for sensitization and early rejection episodes in a DST + azathio-
prine protocol. (abstract) Abstracts of the American Society of
Transplant Surgeons 13th Annual Meeting, 1987, p. 93
47. COLOMBE BW, JUSTER RP, SALVATIERRA 0, GAROVOY MR: Pre-
dicting the likelihood of sensitization for the DST recipient. (ab-
stract) Abstracts of the American Society of Transplant Physicians
6th Annual Meeting, 1987, p. 33
48. KASSIRER JP, PAUKER SO: The toss up. N EngI J Med 305:
1467—1469, 1981
49. KASSIRER JP, MosKowlTz AJ, LAU J, PAUKER SO: Decision
analysis: A progress report. Ann Intern Med 106:275—291, 1987
50. FELLNER CH: Organ donation: For whose sake? Ann Intern Med
79:589—592, 1973
51. SIMMONS RG: Long-term reactions of renal recipients and donors,
in Psychonephrology 2: Psychological Problems in Kidney Failure
and Their Treatment, edited by LEVY NB, New York, Plenum
Press, 1983, pp. 275—287
52. SMITH MD, KAPPELL DF, PROVINCE MA, HONG BA, ROBSON AM,
DUTTON 5, GUZMAN T, HOFF J, SHELTON L, CAMERON E:
Living-related donors: A multicenter study of donor education,
socioeconomic adjustment, and rehabilitation. Am J Kid Dis 8:
223—233, 1986
53. MARSHALL JR, FELLNER CH: Kidney donors revisited. Am J
Psychiatry 134:575—576, 1977
54. YOUNG Mi, BRESNITZ EA, STROM BL: Sample size nomograms for
interpreting negative clinical studies. Ann Intern Med 99:248—251,
1983
55. LEVEY AS, Hou 5, BUSH HL: Kidney transplantation from unre-
lated living donors. Time to reclaim a discarded opportunity. N
EngI J Med 314:914—916, 1986
Jayes and Levey: Related donor transplantation 493
56. SOLLINGER HW, KALAYOGLU M, BELZER FO: Use of the donor-
specific transfusion protocol in living unrelated donor-recipient
combinations. Ann Surg 204:315—321, 1986
57. SOLLINGER HW, BURLINGHAM Wi, SPARKS EM, GLASS NR,
BELZER FO: Donor-specific transfusions in unrelated and related
HLA-mismatched donor-recipient combinations. Transplantation
38:612—615, 1984
Appendix
This appendix contains detailed explanations of I) the Markov
models, 2) the assumptions used in the analysis, 3) the probabilities
used in the decision model, and 4) the calculations used for the annual
probabilities of death and graft failure. The table and reference numbers
correspond to the numbering in the main text.
Markov models of prognosis
The subsequent clinical course of all patients is represented by eight
health states in the Markov model [9, 10], as illustrated in Figure 6.
Circles represent the states of health and quality of life; arrows
represent possible transitions between states during each four-month
cycle. Figure 6A shows all possible transitions and Figure 6B shows
transitions of two patients as examples. Patients sensitized by DST start
in DIALYSIS NO PRIOR GRAFT. Patients not sensitized by DST and
patients in the cyclosporine strategy start in WELL FIRST GRAFT.
The eight states are described below:
I.) DIALYSIS NO PRIOR GRAFT represents patients on dialysis
with no prior failed graft. Possible events in each four-month cycle
include receiving a cadaveric graft, death, or remaining on dialysis.
2.) WELL FIRST GRAFT represents patients with a functioning first
graft from a living-related or cadaver donor. Possible events in each
four-month cycle include graft loss, death, or remaining well with the
first graft.
3.) DIALYSIS ONE PRIOR GRAFT represents patients on dialysis
with one failed prior graft. Possible events in each four-month cycle
include receiving a cadaveric graft, death, or remaining on dialysis.
4.) WELL SECOND GRAFT represents patients with a functioning
second graft. Possible events in each four-month cycle include graft
loss, death, or remaining well with the second graft. We assume that
only one living-related donor graft is possible, so all patients in this state
have cadaveric grafts.
5.) DIALYSIS TWO PRIOR GRAFTS represents patients on dialysis
with two failed prior grafts. Possible events in each four-month cycle
include receiving a cadaveric graft, death, or remaining on dialysis.
6.) WELL THIRD GRAFT represents patients with a functioning
third and final graft. Possible events in each four-month cycle include
graft loss, death, or remaining well with the third graft. All patients in
this state have cadaveric grafts.
7.) DIALYSIS THREE PRIOR GRAFTS represents patients on
dialysis with three failed prior grafts. Patients with three failed prior
grafts cannot receive another graft. Possible events in each four-month
cycle include death or remaining on dialysis.
8.) DEAD represents patients who have died from any cause. There
are no possible transitions to other states.
Figure 6B depicts the clinical course of two patients: one patient
(unbroken arrows) is sensitized by DST, receives a cadaver transplant
after 12 months on dialysis, has a functioning graft for 4 months, but
then dies. Another patient (dotted arrows) is not sensitized by DST, has
a functioning graft for 12 months, resumes dialysis because of graft
failure, but then dies. The patients in Figure 6B each survive for 24
months. However, because the quality of life for each health state is
different, the quality-adjusted survival for these two patients is dif-
ferent. Below, we review the probabilities used for each possible state
transition and the quality of life for each health state.
In the actual Markov model used for the calculations, we represented
each WELL state by four consecutive states (not shown in Fig. 6). The
first three represented the first three four-month intervals after trans-
plantation. The fourth state represented all subsequent four-month
intervals. The reason for this representation is that the probabilities of
death and graft loss are higher in the first year after transplantation than
in all subsequent years. Thus, there are actually 17 states of health and
quality of life.
Assumptions
(I) Patients in the DST strategy are at risk of sensitization to donor
antigens. Azathioprine is administered concurrently with DST in order
to minimize sensitization. Sensitized patients do not receive a living
related graft; instead they continue dialysis while awaiting a cadaver
graft.
(2) The probability of obtaining a cadaver transplant in each year after
sensitization is constant. Patients receiving a cadaver graft are immu-
nosuppressed with cyclosporine and prednisone.
(3) Patients in the cyclosporine strategy are not at risk of sensitization
to their living-related donor. All obtain a living related graft.
(4) The risks of death and graft failure during the first year following
transplantation are identical for both strategies. Thereafter the annual
risks are constant. The risk of death in subsequent years is identical for
both strategies; but as discussed later, graft failure in subsequent years
is higher for patients in the cyclosporine strategy due to the long-term
nephrotoxicity of cyclosporine. Risks of death and graft loss in all years
following cadaver transplantation are higher than for living-related
transplantation.
(5) In practice, patients change between cyclosporine and azathio-
prine immunosuppression because of complications. However, the data
that we employed in this analysis were reported according to the
patient's original immunosuppressive therapy. Hence, we have not
explicitly modelled these changes; patients remain identified according
to their original therapy.
(6) Patients with graft failure resume dialysis and await cadaver
transplantation. The annual probability of obtaining a cadaver graft for
patients with previous graft failure is constant and lower than for
patients sensitized by DST who are awaiting their first graft. We
assumed that patients would not receive more than three grafts. If a
third graft fails, the patient remains on dialysis.
(7) We did not consider combined treatment with DST and cyclo-
sporine. Currently, there is little enthusiasm for this strategy due to
concern that the combined disadvantages of the two treatments may
outweigh any advantages.
Probabilities
Probability of sensitization with DST. With administration of azathi-
oprine during donor-specific transfusions, the risk of sensitization is
approximately 15% [11—13]. We took the probability of sensitization to
be 12%, which is lower than the probability that appears in most
reports. This introduces a bias in favor of the DST strategy.
Probability of cadaver transplantation. The probability of obtaining a
cadaveric kidney is influenced by the recipient's blood type, tissue
type, prevalence of antibodies reactive against donor antigens, and the
supply of cadaver donors. Both sensitization by DST and rejection of
kidney transplants are associated with the development of antibodies
reactive against potential donors [14, 15]. Presently, there are more
than twice as many patients awaiting cadaver kidneys each year as
there are cadaver kidneys procured [16]. As a result of the shortage of
cadaver kidneys, many patients experience a long wait before receiving
a cadaver graft. We assumed a constant annual probability of receiving
a cadaver transplant of 0.5 after sensitization by DST and 0.1 after
failure of a first or subsequent transplant.
Probability of death for patients on dialysis. We calculated this
probability from the survival of patients aged 35 to 55 years treated by
dialysis reported by the Medicare End-Stage Renal Disease Program
[17]. These data indicate that the annual probability of death from all
causes is relatively constant over an interval of approximately 10 years.
We used an annual probability of 10% for all years, which is similar to
the value from other reports [18—23]. We used the same probability for
patients on dialysis awaiting transplantation and for patients resuming
dialysis after graft failure because the mortality during these two
periods is similar [24].
Probability of death and graft failure after transplantation: First
year. The first year survival of patients and grafts after transplantation
has improved dramatically in recent years. The probabilities of death
and graft failure are lowest in recipients of living-related grafts, inter-
mediate in recipients of first cadaver grafts, and highest in recipients of
second and subsequent grafts. For living-related graft recipients, we
took the probabilities of death and graft failure to be 0.030 and 0.060,
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Fig. 6. The Markov model. A. All possible
transitions during the first six four-month
cycles are depicted.
respectively, whether they undergo treatment with DST or cyclospo-
rifle. For recipients of first cadaver grafts, the probabilities of death and
graft failure are 0.050 and 0.190, respectively. For recipients of second
and subsequent grafts, the probabilities of death and graft loss are 0.080
and 0.250, respectively. These values were derived from reports of
large national and international registries [13, 22, 25].
Subsequent years. Long-term data are available from the UCLA
registry for large numbers of patients treated with azathioprine and
prednisone [26]. After the first year following transplantation, the
annual probabilities of death and graft failure are relatively constant
over a ten year interval. We used these data to calculate constant values
for the annual probabilities of death and graft failure. The method of
calculation is described below. For living related graft recipients, the
probabilities were determined to be 0.037 and 0.026, respectively; and
for cadaveric graft recipients, 0.056 and 0.034, respectively. These
values were used for patients in the DST strategy treated with azathi-
oprine and prednisone (Table 1). They were also used to calculate
probabilities for patients treated with cyclosporine, as described below.
Presently, there are not sufficient long-term data from which to
calculate the probabilities of death and graft loss in subsequent years
after transplantation in patients treated with cyclosporine. Cyclospo-
rine was introduced for clinical transplantation in 1978, but not ap-
proved for use in the United States until 1983, so only a few reports
contain even five-year follow-up data. We assumed the risk of death in
subsequent years after transplantation for patients receiving cyclospo-
rine is the same as for patients treated with azathioprine: 0.037 and
0.056 per year in living related and cadaver graft recipients respectively.
We assumed that graft failure in subsequent years in patients treated
with cyclosporine results from two mechanisms: I) rejection caused by
differences in tissue matching between the recipient and donor; and 2)
nephrotoxicity of cyclosporine. We represented these two mechanisms
by two independent probabilities: the annual probability of graft failure
from rejection and the annual probability of graft failure from cyclo-
sporine nephrotoxicity. We assumed that patients treated with cyclo-
sporine have an annual probability of graft failure equal to the sum of
these two probabilities. For the probability of rejection, we used the
annual probability of graft failure in patients treated with azathioprine
for living-related and cadaveric transplant recipients, 0.026 and 0.034,
respectively, as discussed earlier. As discussed below, we took the
annual probability of graft loss due to cyclosporine toxicity to be either
A
Time
month
0
24
812
16
20
Jayes and Levey: Related donor transplantation 495
Fig. 6B. Examples of transitions for two
hypothetical patients are shown.
0.001 or 0.010, Therefore the probability of graft loss for living-related
transplants was taken as 0.027 or 0.036, and for cadaver transplants
0.035 or 0.044 (Table I). This assumption biases the analysis in favor of
the DST strategy because it overlooks the fact that cyclosporine,
compared to azathioprine, has been associated with a lower probability
of graft failure in numerous randomized clinical trials in cadaver
transplantation [27—30]. We made this assumption in order to avoid
overlooking an advantage of DST, the conventional strategy.
Probability of graft failure due to cyclosporine nephrotoxicity. De-
spite its superior immunosuppressive efficacy, there is serious concern
about possible long-term toxicity of cyclosporine. Marked structural,
functional and clinical renal abnormalities have been demonstrated in
patients receiving this agent as immunosuppressive therapy for heart,
liver and bone marrow transplants, and for various autoimmune dis-
eases [3 1—33]. Structural abnormalities include acute and chronic inter-
stitial inflammation, fibrosis, and occasionally small vessel thrombosis.
Functional alterations include reduced renal blood flow, glomerular
filtration rate and prostaglandin production. Clinical evidence of toxic-
ity includes higher levels of blood pressure and serum creatinine. The
most serious evidence of toxicity has been reported in patients receiv-
ing high doses (15 to 20 mg/kg/day) for heart transplantation. In these
patients, severe interstitial fibrosis has been demonstrated, associated
with progressive increase in serum creatinine and the development of
renal failure in some cases [34]. However, more recent heart transplan-
tations, in which lower doses (5 to 10 mglkg/day) of cyclosporine were
used, have not been associated with progressive deterioration in renal
function or renal failure [35]. In patients treated for autoimmune
diseases, manifestations of toxicity have varied in severity. Patients
with uveitis receiving doses of 10 mg/kg/day for two or more years have
evidence of permanent alterations in renal structure and function,
including interstitial fibrosis and reduced creatinine clearance. Thus far,
no patients have developed renal failure [36]. Patients treated with
doses of 5 to 10 mg/kg/day for rheumatoid arthritis [37], systemic lupus
erythematosus [38] and recent-onset juvenile diabetes mellitus [39] have
demonstrated transient elevations in serum creatinine or blood pres-
sure, but permanent alterations have not been observed.
The toxic effects of cyclosporine are most difficult to discern in
kidney transplant recipients, in whom the same structural, functional,
and clinical alterations are the hallmarks of chronic rejection. Revers-
ible alterations in glomerular filtration rate, renal blood flow, serum
B
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creatinine concentration and arterial blood pressure have been well
documented [3 1—33]. However, it is not determined if permanent and
progressive alterations in renal structure and function are more com-
mon in patients receiving cyclosporine. Thus far, there is no indication
that patients treated with cyclosporine have a higher risk of graft failure
following transplantation than do comparable patients treated with
azathioprine and prednisone [40, 41].
In summary, although it has been clearly demonstrated that cyclo-
sporine has toxic effects, the magnitude of the long-term effects on graft
survival is uncertain. For our analysis, we assumed that cyclosporine is
associated with an increased annual probability of graft failure after the
first year; a deliberate bias in favor of the DST strategy. We selected
two values for the annual probability of graft failure due to cyclosporine
nephrotoxicity (Table 1): 1) 0.001, or one failed graft per 1000 patients
per year, which corresponds to the annual probability of graft failure
after the first year in recipients of kidneys from two-haplotype matched
living-relatives treated with azathioprine and prednisone [26]. This
represents the long-term deleterious effects on graft survival due to
minimal differences in tissue matching. We consider this to be a likely
minimal estimate of long-term nephrotoxicity of cyclosporine. 2)0.010,
an annual probability that is ten times greater, or one failed graft per 100
patients per year, which corresponds approximately to the difference in
annual probabilities of graft failure after the first year between recipi-
ents of kidneys from one-haplotype matched living-relatives and from
unrelated cadaver donors treated with azathioprine and prednisone
[26]. This represents the difference in long-term deleterious effects of
greater differences in tissue matching. We consider this to be a likely
maximal estimate of the long-term nephrotoxicity of cyclosporine.
However, because the actual effect of cyclosporine is unknown, we
examined a broader range of probabilities in the sensitivity analysis.
Calculation of the annual probability of death and graft
failure
Actuarial patient and graft survival curves for renal transplants
decline exponentially after about the first year following transplantation
[4, 5]. From these curves we calculated the annual rates of death and
graft failure after the first year by using the formula:
annual rate =
—ln(fraction surviving)/time in years.
The annual probabilities shown in Table I were calculated from the
annual rates using the formula:
annual probability = 1 — e(at rate x I year)
where e is the base of the natural logarithm 2.718. The four-month
probabilities were calculated from the annual probabilities using the
formula:
four-month probability = I — (I — annual probabiIity)°33 Ycart)
For example, survival of recipients of living-related kidneys declines
exponentially with a half-life of 19 years [4]. Therefore the annual rate
of death is —ln(0.5)/19 years or 0.0365 deaths/year. The annual proba-
bility is 1 — e°°365 >< I year) or 0.037 (Table 1). The four-month
probability used in the Markov model is: 1 — (I — 0.037)° years) or
0.0125.
